Hims & Hers Health's Model 'Proving Effective': 2 Analysts Examine Q1 Earnings
Hims & Hers Health's Model 'Proving Effective': 2 Analysts Examine Q1 Earnings
Shares of Hims & Hers Health Inc (NYSE:HIMS) were climbing in early trading on Tuesday. The personal-care products company reported upbeat results for the first quarter.
周二早盘，Hims & Hers Health Inc（纽约证券交易所代码：HIMS）的股价上涨。这家个人护理产品公司公布了第一季度业绩乐观。
The results be reported amid an exciting earnings season. Here are some key analyst expectations.
业绩将在激动人心的财报季中公布。以下是分析师的一些主要预期。
- Piper Sandler analyst Korinne Wolfmeyer maintained a Neutral rating, while raising the price target from $11 to $13.
- Truist Securities analyst Jailendra Singh reaffirmed a Hold rating and price target of $13.
- 派珀·桑德勒分析师科琳娜·沃尔夫迈耶维持中性评级，同时将目标股价从11美元上调至13美元。
- Truist Securities分析师贾伦德拉·辛格重申了13美元的持有评级和目标股价。
Check out other analyst stock ratings.
查看其他分析师股票评级。
Piper Sandler: Hims & Hers Health reported total revenue of $278.2 million. That represents 46% year-on-year growth and higher than Street expectations of $270.4 million, Wolfmeyer said in a note.
派珀·桑德勒：Hims & Hers Health公布的总收入为2.782亿美元。沃尔夫迈耶在一份报告中表示，这意味着同比增长46％，高于华尔街预期的2.704亿美元。
The San Francisco-based company also delivered a beat on adjusted EBITDA, "driven entirely by impressive SG&A leverage," he added.
他补充说，这家总部位于旧金山的公司也实现了调整后的息税折旧摊销前利润，“完全是由可观的销售和并购杠杆率推动的”。
The results indicate that the company's model is "proving effective," the analyst wrote. Management raised their 2024 revenue and adjusted EBITDA guidance by more than the beat, from $1.17-$1.20 billion to $1.20-$1.23 billion and from $100-$120 million to $120-$135 million, respectively.
分析师写道，结果表明，该公司的模型 “被证明是有效的”。管理层将2024年的收入和调整后的息税折旧摊销前利润预期提高幅度超过预期，分别从11.7亿美元至12.0亿美元至12.3亿美元，从1亿至1.2亿美元增至1.2亿美元至1.25亿美元。
The company delivered a strong quarter "with little to pick at." In case the "top line momentum doesn't hold, the margin progression is at risk," Wolfmeyer further stated.
该公司的季度表现强劲，“几乎没有什么可选择的”。沃尔夫迈耶进一步表示，如果 “收入势头不变，利润率增长将面临风险”。
Truist Securities: Hims & Hers Health reported a beat and raise quarter, "driven by a strong subscriber growth, continuing increase in the percentage of subscribers opting for personalized solutions, and efficiency improvements," Singh wrote in a note.
Truist Securities：Hims & Hers Health报告称，“受用户强劲增长、选择个性化解决方案的订户比例持续增加以及效率提高的推动，” 辛格在一份报告中写道，本季度业绩表现良好。
Subscribers grew by 41% to 1.709 billion, with increasing penetration of personalized solutions, the analyst stated.
分析师表示，随着个性化解决方案的渗透率不断提高，订户增长了41％，达到17.09亿。
"This year, HIMS will continue to expand its range of personalized solutions in both established and newer specialties in areas like Weight Loss and Dermatology to enhance the customer experience with more user-friendly form factors and eventually, a broader selection of multi-action offerings," he further wrote.
他进一步写道：“今年，HIMS将继续扩大其在减肥和皮肤病学等领域成熟和新兴专业领域的个性化解决方案范围，以通过更人性化的外形来增强客户体验，最终提供更广泛的多功能产品选择。”
HIMS Price Action: Shares of Hims & Hers Health had risen by 5.97% to $12.34 at the time of publication on Tuesday.
HIMS价格走势：在周二发布时，Hims & Hers Health的股价上涨了5.97％，至12.34美元。
Now Read: Taylor Swift Vs. Scooter Braun – New Docuseries On Bitter Music Feud To Skip US Launch
立即阅读：泰勒·斯威夫特 vs.Scooter Braun — 关于苦乐争执的新纪录片系列将跳过美国上映时间